Rucaparib (Rubraca, Pharm&) is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy'.
The dosage schedule is available in the summary of product characteristics for rucaparib.
The list price of rucaparib is £3,562 per 60‑tablet pack of 300‑mg, 250‑mg or 200‑mg tablets (excluding VAT, BNF online, accessed August 2024).
The company has a commercial arrangement. This makes rucaparib available to the NHS with a discount. The size of the discount is commercial in confidence.